Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107Przemyslaw Twardowski, Primo N. Lara, Catherine M. Tangen et al.|Kidney Cancer|2017Cited by 41